Robert Coleman
The US Oncology Network · NRG Oncology · M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Robert Coleman as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:57 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT04296890 · A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha ExpressionImmunoGen, Inc. · completed · Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer · principal investigator
- Ph2NCT01540565 · Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerNational Cancer Institute (NCI) · completed · BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ovarian Epithelial Tumor · principal investigator
- Ph1NCT01440998 · Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial CancerNational Cancer Institute (NCI) · completed · Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma · principal investigator
- Ph2NCT01011933 · Selumetinib in Treating Patients With Recurrent or Persistent Endometrial CancerNational Cancer Institute (NCI) · completed · Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma · principal investigator
- Ph2NCT00499252 · Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerGynecologic Oncology Group · completed · Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma · principal investigator
- Ph2NCT00462826 · VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial CancerNational Cancer Institute (NCI) · completed · Recurrent Endometrial Carcinoma · principal investigator
- Ph1/Ph2NCT00436501 · VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerNational Cancer Institute (NCI) · completed · Fallopian Tube Cancer, Malignant Tumor of Peritoneum, Recurrent Ovarian Epithelial Cancer · principal investigator
- Ph2NCT00414076 · Letrozole Versus Observation in Patients With Newly Diagnosed Uterine LeiomyosarcomaM.D. Anderson Cancer Center · terminated · Leiomyosarcoma, Uterine Neoplasm · principal investigator
- Ph1NCT00407407 · ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CarcinomaCelgene · terminated · Fallopian Tube Neoplasms, Peritoneal Neoplasms, Ovarian Neoplasms · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:57 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 8 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Project 3: The Role of Macrophages in Resistance to Anti-VEGF Drugs in Ovarian CancerP50CA217685 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2017 to 2018 · $370,464 awarded in 2018Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- NRG Oncology Network Group Operations CenterU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Quynh-Thu Xuan Le, ROBERT S. MANNEL, NORMAN WOLMARK · fiscal years 2017 to 2026Named on NCT01540565, NCT01011933
- U10CA027469RePORTER returned no project for this number; it is shown as the registry gives it.
- Experimental Medicine ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM · fiscal years 2017 to 2026Named on NCT01440998
- MD Anderson Gynecologic SPORE for Uterine CancersP50CA098258 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI RUSSELL R BROADDUS, Karen Hsieh Lu · fiscal years 2017 to 2020Named on NCT01440998
- P50CA083639RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT00436501
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:57 UTC. The ranking covers the 200 most relevant of 385 PubMed records, and a shared surname and initials can bring in a namesake. All 385 on PubMed
- Alpha emitter radium-223 and survival in metastatic prostate cancer.N Engl J Med · 20132,625 citationsRCR 81.4
- 1,425 citationsRCR 76.7
- 1,419 citationsRCR 44.3
- Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.N Engl J Med · 2023744 citationsRCR 66.0
- Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.N Engl J Med · 2019733 citationsRCR 27.1
- Adjuvant docetaxel for node-positive breast cancer.N Engl J Med · 2005705 citationsRCR 16.2
- Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.J Clin Oncol · 1997542 citationsRCR 14.1
- Adjuvant ovarian suppression in premenopausal breast cancer.N Engl J Med · 2015541 citationsRCR 16.8
- Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.N Engl J Med · 2018529 citationsRCR 20.2
- Pathologic fractures correlate with reduced survival in patients with malignant bone disease.Cancer · 2007519 citationsRCR 13.0